143 related articles for article (PubMed ID: 10925290)
1. The MHC class II molecule I-Ag7 exists in alternate conformations that are peptide dependent.
Arneson LS; Peterson M; Sant AJ
J Immunol; 2000 Aug; 165(4):2059-67. PubMed ID: 10925290
[TBL] [Abstract][Full Text] [Related]
2. The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder.
Stratmann T; Apostolopoulos V; Mallet-Designe V; Corper AL; Scott CA; Wilson IA; Kang AS; Teyton L
J Immunol; 2000 Sep; 165(6):3214-25. PubMed ID: 10975837
[TBL] [Abstract][Full Text] [Related]
3. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
4. The inability of the nonobese diabetic class II molecule to form stable peptide complexes does not reflect a failure to interact productively with DM.
Peterson M; Sant AJ
J Immunol; 1998 Sep; 161(6):2961-7. PubMed ID: 9743359
[TBL] [Abstract][Full Text] [Related]
5. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
6. The role of I-Ag7 beta chain in peptide binding and antigen recognition by T cells.
Kanagawa O; Shimizu J; Unanue ER
Int Immunol; 1997 Oct; 9(10):1523-6. PubMed ID: 9352357
[TBL] [Abstract][Full Text] [Related]
7. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
8. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes.
Gregori S; Trembleau S; Penna G; Gallazzi F; Hammer J; Papadopoulos GK; Adorini L
J Immunol; 1999 Jun; 162(11):6630-40. PubMed ID: 10352280
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice.
Latek RR; Suri A; Petzold SJ; Nelson CA; Kanagawa O; Unanue ER; Fremont DH
Immunity; 2000 Jun; 12(6):699-710. PubMed ID: 10894169
[TBL] [Abstract][Full Text] [Related]
10. Nonobese diabetic mice display elevated levels of class II-associated invariant chain peptide associated with I-Ag7 on the cell surface.
Bhatnagar A; Milburn PJ; Lobigs M; Blanden RV; Gautam AM
J Immunol; 2001 Apr; 166(7):4490-7. PubMed ID: 11254705
[TBL] [Abstract][Full Text] [Related]
11. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders.
Carrasco-Marin E; Shimizu J; Kanagawa O; Unanue ER
J Immunol; 1996 Jan; 156(2):450-8. PubMed ID: 8543793
[TBL] [Abstract][Full Text] [Related]
12. pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH.
Hausmann DH; Yu B; Hausmann S; Wucherpfennig KW
J Exp Med; 1999 Jun; 189(11):1723-34. PubMed ID: 10359576
[TBL] [Abstract][Full Text] [Related]
13. Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide.
Gardiner A; Richards KA; Sant AJ; Arneson LS
Int Immunol; 2007 Sep; 19(9):1103-13. PubMed ID: 17855434
[TBL] [Abstract][Full Text] [Related]
14. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes.
Corper AL; Stratmann T; Apostolopoulos V; Scott CA; Garcia KC; Kang AS; Wilson IA; Teyton L
Science; 2000 Apr; 288(5465):505-11. PubMed ID: 10775108
[TBL] [Abstract][Full Text] [Related]
15. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
16. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
17. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
18. Self peptides isolated from MHC glycoproteins of non-obese diabetic mice.
Reich EP; von Grafenstein H; Barlow A; Swenson KE; Williams K; Janeway CA
J Immunol; 1994 Mar; 152(5):2279-88. PubMed ID: 8133041
[TBL] [Abstract][Full Text] [Related]
19. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
20. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
